RT Journal Article
SR Electronic
T1 Introduction of Dengue Virus Serotype 3 in the Afar Region, Ethiopia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.19.24310689
DO 10.1101/2024.07.19.24310689
A1 Mekonnen, Feleke
A1 Khan, Bilal A.
A1 Nibret, Endalkachew
A1 Munshea, Abaineh
A1 Tsega, Daniel
A1 Endalamaw, Demeke
A1 Tadesse, Senait
A1 Yismaw, Gizachew
A1 Lankir, Damtie
A1 Ali, Jemal
A1 Ulinici, Mariana
A1 Orsini, Emanuele
A1 Susnjar, Ursa
A1 Carletti, Tea
A1 Licastro, Danilo
A1 Bitew, Molalegne
A1 Giovanetti, Marta
A1 Marcello, Alessandro
YR 2024
UL http://medrxiv.org/content/early/2024/07/21/2024.07.19.24310689.abstract
AB The genetic analysis of the Dengue virus circulating in Ethiopia’s Afar region, in 2023, identified three distinct introductions with spatiotemporal clustering linked to genomes from Asia and Italy. These findings are crucial for enhancing prevention and control strategies, reinforcing the necessity to provide sustainable tools for genomic epidemiology in Africa.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported, in whole or in part, by the Bill & Melinda Gates Foundation [Grants No. INV-034,799 and INV-064464]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. Other sources of funding include the ICGEB CRP to Ethiopia (CRP/ETH21-01) and PNRR GENESIS - COC-1-2023-UNIPV - ID S1.P0002 (INF-ACT). The content and findings reported in this work are the sole responsibility of the researchers involved and do not necessarily reflect the official positions or sentiments of the funding agencies that supported this project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Regional Public Health Research Ethics Review Committee, Ethiopia, approved the study (Ref. NoH/R/T/T/D/07/39).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.